| Gazyva (obinutuzumab) / Roche, Biogen |
| Recruiting | 1 | 537 | Europe, US, RoW | BGB-11417, Sonrotoclax, Zanubrutinib, BGB-3111, obinutuzumab | BeiGene | Mature B-Cell Malignancies | 08/27 | 08/27 | | |
NCT05845762: Obinutuzumab in the Management of Idiopathic Membranous Nephropathy |
|
|
| Not yet recruiting | N/A | 30 | NA | Obinutuzumab Injection, Obinutuzumab | Qianfoshan Hospital | Idiopathic Membranous Nephropathy | 12/23 | 12/23 | | |
URBAN, NCT04034056: Untreated FolliculaR Lymphoma Treated With OBinituzumAb in a Non-interventional Study |
|
|
| Completed | N/A | 299 | Europe | Obinutuzumab | Hoffmann-La Roche | Follicular Lymphoma | 04/24 | 04/24 | | |
NCT05797948: GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma |
|
|
| Enrolling by invitation | N/A | 20 | RoW | Obinutuzumab, Gazyva, Zanubrutinib, Brukinsa, Lenalidomide, Anxian, CD19/CD22 CAR-T, Azacitidine For Injection, Anyve, Fludarabine, Fludara, Cyclophosphamide, Endoxan | The First Affiliated Hospital of Soochow University | Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | 06/24 | 06/24 | | |
| Recruiting | N/A | 104 | RoW | | Healthy Future | Chronic Lymphocytic Leukemia | 08/24 | 04/25 | | |
NCT05968001: Obinutuzumab in Chinese Real-world Patients With iNHL |
|
|
| Not yet recruiting | N/A | 400 | RoW | Obinutuzumab | Affiliated Hospital of Nantong University | Lymphomas Non-Hodgkin's B-Cell | 12/24 | 07/26 | | |
NCT05899621: A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL |
|
|
| Recruiting | N/A | 332 | RoW | Obinutuzumab, Lenalidomide, Bendamustine, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone | Ruijin Hospital | Follicular Lymphoma | 06/25 | 06/27 | | |
NCT05846763: Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study |
|
|
| Recruiting | N/A | 50 | RoW | | Institute of Hematology & Blood Diseases Hospital | Follicular Lymphoma | 05/26 | 05/28 | | |
NCT05950997: A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL |
|
|
| Recruiting | N/A | 89 | RoW | Acalabrutinib, Obinutuzumab | The First Affiliated Hospital with Nanjing Medical University, AstraZeneca | Chronic Lymphocytic Leukemia | 05/26 | 09/26 | | |
ARIADNE, NCT05326308: Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma |
|
|
| Recruiting | N/A | 400 | Europe | Zanubrutinib, Brukinsa®, Obinutuzumab, Gazyvaro® | iOMEDICO AG, BeiGene Switzerland GmbH | Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma, Follicular Lymphoma | 04/27 | 04/27 | | |